Aβ42/ Aβ40 (Plasma)
Cross-sectional and longitudinal analyses showed an inverse association of Aβ42/40 plasma ratios and cortical Aβ burden. These findings support the use of plasma Aβ42/40 ratios as surrogate biomarkers of cortical Aβ deposition and enrichment tools, reducing the number of subjects submitted to invasive tests and, consequently, recruitment costs in clinical trials targeting cognitively normal individuals.
blood draw, mild discomfort, in clinic visits
phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)
R&D Department, Araclon Biotech Ltd., Zaragoza, Spain; Aragon Institute of Engineering Research, University of Zaragoza, Zaragoza, Spain; The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia;CSIRO Health and Biosecurity/Australian E-Health Research Centre, Brisbane, Queensland, Australia
-
Fandos, N., Pérez-Grijalba, V., Pesini, P., Olmos, S., Bossa, M., Villemagne, V. L., ... & AIBL Research Group. (2017). Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 8, 179-187. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602863/
- Sharma, N., & Singh, A. N. (2016). Exploring biomarkers for Alzheimer’s disease. Journal of clinical and diagnostic research: JCDR, 10(7), KE01. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020308/